This Privacy Notice explains what type of personal data we may collect from you and how we use it when you enrol in REVESTIVE^® atHOME^® (the “Program”).
The Program is a free service developed by Takeda and managed by Nexus Australasia Pty Ltd, trading as Zest Healthcare Communications (“Zest”). Nursing staff for the program will be provided by private nursing company ASCOTT Sales Integration Pty Ltd (“ASCOTT”), (“Providers” or “we” collectively). The Program aims to provide support for patients who have been prescribed REVESTIVE (teduglutide) for short bowel syndrome with intestinal failure (SBS-IF) and who are living in Australia. The Program offers nursing support, delivery of ancillaries, and an online portal and treatment progress diary to help your healthcare team monitor your parenteral support needs.

How your personal data is collected, used, and stored

We collect and use personal data about you as may be required for the purposes of the Program, and to respond to or fulfil your requests. The personal data we may collect includes, but is not limited to, your contact information, delivery address, treatment, and treatment schedule, and any other information relevant to your participation in the Program. The personal data may be provided by you, or collected from healthcare professionals involved in your treatment, including your treating doctor, nurses, pharmacists and dietitians. We may not be able to provide you services under the Program if your personal data is not collected.
Information about your participation in the Program and healthcare needs may be shared with others, such as the healthcare professionals involved in your treatment, or the partners we work with to provide you this Program and the services under it. We may also use or disclose your personal data as needed to comply with regulatory requirements. This includes reporting of safety information to relevant regulatory authorities and/or Takeda.
Information about you will only be shared with Takeda in de-identified, aggregated reports for the purpose of program administration, monitoring and health technology assessments. Otherwise, Takeda will generally not be provided access to your personal data, unless required by law, or if necessary to ensure the integrity and continued provision of the Program. Information on how Takeda processes personal data is available at www.takeda.com/privacy-notice.
We store your personal data in Australia. The sharing of personal data as described above may involve transfers to other countries. The data protection and privacy laws in such countries may provide a different level of protection. We will put in place appropriate safeguards to protect personal data in connection with such transfers. For more detailed information on how Zest uses, stores and discloses personal data, please refer to Zest’s Privacy Policy at www.zest.com.au/privacy-policy.

How long is my personal data retained?

Your personal data will be retained by Zest and ASCOTT for at least seven years, or as required by applicable law after you have ended your participation in the Program or after the Program has ended, whichever is shortest. After this period, your personal data will be securely deidentified and archived or destroyed.

Your rights regarding your personal data

You can request access to your personal data. You may correct errors or request that your personal data be erased or make a privacy complaint. Contact the Zest Privacy Officer via email at privacy@symbion.com.au, and the ASCOTT Privacy Officer via email at privacyofficer@iqvia.com who will respond to your request within the timeframes required by applicable laws and/or as soon as reasonable.

REVESTIVE atHOME Privacy Notice

Your privacy is important to us. Takeda recognises and respects the privacy rights of individuals with regards to their personal data. This Privacy Notice and Consent form (“Form”) explains what type of personal data we may collect from you and how we use it when you enrol in REVESTIVE atHOME (the “Program”). Such information is subject to applicable privacy requirements.

The Program is a free service provided to you by Takeda and will be performed by Zest Healthcare Communications (“Zest”) with full collaboration from participating hospitals. Nursing staff for the program will be provided by private nursing company, IQVIA Solutions Australia Pty Ltd, trading as Ascott Sales Integration Pty Ltd (“ASCOTT”), (“Providers” collectively). For more details see How to Contact Us section below.

For more detailed information on how Takeda processes personal data, please refer to Takeda’s Privacy Notice at www.takeda.com/privacy-notice. For more detailed information on how Providers process personal data, please refer to Providers’ Privacy Notice at Zest www.zest.com.au/privacy-policy and ASCOTT www.iqvia.com/about-us/privacy.

Before enrolling in the Program, you should read this entire Form. At the end of this Form, you will be asked to consent to the processing of your personal data by signing this Form. If you do not sign this Form, it will not be possible to enrol in the Program.

In this document, process means to perform any operation or set of operations on personal data or sets of personal data, whether or not by automatic means, such as collection, recording, organisation, structuring, storage, access, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, evaluation, analysis, reporting, sharing, alignment or combination, restriction, erasure or destruction.

REVESTIVE atHOME Patient Support Program

The REVESTIVE atHOME program provides support for your REVESTIVE treatment through the provision of services such as home nursing support; the option to have your REVESTIVE pack and reconstitution and injection ancillaries (such as needles and swabs) delivered to your home or your local pharmacy; and an online portal and treatment progress diary to help your healthcare team monitor your parenteral support needs.

What personal data will be collected?

We will only collect personal data about you that is required to perform the Program as described above. The personal data collected includes, but is not limited to, your contact information, details of your emergency contact, carer or parent/guardian as relevant, your multidisciplinary team, your hospital or SBS-IF clinic, some medical information about you (comprising information on your SBS history, the reasons why you had to undergo resection surgery and other parts of your medical history relevant to treatment with REVESTIVE) and includes the meaning given to “Personal Information” under applicable privacy laws in Australia. This personal data will be collected by Zest and ASCOTT and may include the collection of personal data relevant to your participation from your prescribing physician or other healthcare professionals, including but not limited to your nurses, dietitian or pharmacists. If you choose to allow us, Zest may also contact you by email or telephone to discuss your experiences and satisfaction with REVESTIVE and the Program.

What happens with my personal data?

If you decide to enrol in the Program, your personal data, including health-related information will be used by Zest and ASCOTT as described based on your consent.

Information about your participation in the Program and results may also be shared back to your treating doctor, and your managing multidisciplinary team. This information will be stored securely in an electronic format on a server in Australia. The Providers administering the service will access the information needed to fulfil regulatory requirements for the reporting of safety information, to coordinate the services and relay information about these to your doctor and hospital.

Takeda will not access your personal data unless required by law, if there is a change in Provider or where required to ensure the integrity and proper administration of the Program.

To protect your privacy, a code will be assigned to your personal data that is shared with Takeda (as opposed to your name or other identifying information) for purposes of safety information reporting, program monitoring and administration. The code will be assigned by authorised personnel at Zest. Only they will be able to connect this number to your name, and they will securely maintain the key that links your identification number to your name. Information about you will only be shared with Takeda in aggregated reports for the purpose of program administration, monitoring and safety reporting.

Your personal data may be sent to countries around the world where Takeda and the Providers have an affiliate or business partner. The data protection and privacy laws in these countries may not provide the same level of data protection as the laws in your home country or the country where you are participating in the Program.

With respect to transfers to its affiliates and business partners located outside of your home country, Takeda and the Providers have entered or will enter into specific agreements with these parties to provide appropriate protections for your transferred information.

How will my personal data be protected?

The Providers will protect your personal data in accordance with all applicable privacy requirements. We take steps to ensure that your personal data is secured against unauthorised access. Security measures reduce the risk of unauthorised individuals accessing your personal data, but such risks cannot be eliminated, and you should keep in mind that no internet transmission is ever completely secure or error free. If your personal data were to be accessed by unauthorised individuals, information about you could be used to make decisions which may be unfavourable to you. Many, but not all, possible unfavourable uses of your re-identified or improperly disclosed information are prohibited by medical ethics, law or regulation.

How long will my personal data be retained?

Your personal data will be retained by the Providers for at least ten years, or as required by applicable law, after you have ended your participation in the Program or after the Program has ended, whichever is shortest. After this period, your personal data will be securely deidentified and archived or destroyed. Takeda will retain aggregated data about the Program for the purpose of fulfilling regulatory obligations under applicable law.

My rights regarding my personal data

You have the right to request access to your personal data, request corrections of any errors in recorded personal data, or where personal data may be missing or incomplete, ask that it be completed. You also have the right to ask that your personal data collected and used for the Program to be erased or that its use be restricted. You can contact the Providers for such requests who will in turn contact Takeda, and we will ensure that we respond to your request within the timeframes required by applicable laws and/or as soon as we reasonably can.

If you make a request for access, correction, completion, erasure, or restriction and it cannot be fulfilled, you will be informed and provided with the reasons why your requests cannot be fulfilled.

For complaints about privacy, we will establish in consultation with you a reasonable process, including timeframes provided by applicable laws, for seeking to resolve your complaint.

Can I withdraw from the Program?

The consent to process your personal data for this Program may be withdrawn at any time without giving any reasons and without any penalty or loss of any benefits to which you are otherwise entitled; however, to the extent that consent is necessary to provide the services under the Program, your participation in the Program may be terminated.

If you want to withdraw, please contact ZEST– see How to Contact Us section below.

How to contact us?

Takeda does not receive any directly identifiable information about you; we therefore request you to contact the Providers for questions and not contact Takeda directly:

• The ZEST Privacy Officer via email at privacy@symbion.com.au
• The ASCOTT Privacy Officer may be contacted via email at privacyofficer@iqvia.com

Patient or parent/guardian consent to Privacy Notice

By signing this consent form, I acknowledge that I have read and understood the information above and that I have been informed of and consent to the following:

• My personal data, including health information will be processed by the Providers; in accordance with applicable privacy requirements in Australia
• My personal data only being shared with relevant parties providing this service in accordance with the Privacy Notice
• My personal data will be processed and transferred to others, like our consultants, agents, contractors and service providers and other companies within the Takeda group, both within and outside of my home country (including the countries shown on Takeda’s website www.takeda.com/countries in which Takeda operates ), as well as to authorities as needed to comply with law or regulatory requirements
• My personal data may be sent to countries around the world where Takeda and the Providers have an affiliate or business partner and such countries may not provide the same level of data protection as the laws in my home country
• I understand that Takeda’s privacy policy located at www.takeda.com/privacy-notice provides further details about Takeda’s privacy practices
• I understand that it is my responsibility to ensure I have the consent of other individuals before sharing their personal data with the Providers e.g. emergency contact/caretaker’s contact details
• I understand that my participation is voluntary, and I can withdraw my consent at any time without providing any reason

Terms and Conditions

• Your doctor has explained the Program to you; you understand and consent to participating in the REVESTIVE atHOME program including home visits provided by a qualified nurse from ASCOTT
• You agree to communications via SMS, email and phone from the REVESTIVE atHOME program coordinator (Zest) for confirmation of appointments, delivery of orders, satisfaction surveys and to follow-up on any adverse events identified as part of this program, which may include Takeda contacting your healthcare team about adverse events
• You agree to communication between the Nurse Care Manager, atHOME nurse and your healthcare team regarding your therapy
• You agree to transition to virtual support from your Nurse Care Manager when you have experience managing your REVESTIVE treatment and are competent and confident to manage your treatment with virtual support only
• You understand that this program does not oblige you to continue your current treatment, but if your treatment changes you may no longer be eligible for this program
• You understand that you can opt out of the program and its services at any time by consulting with your doctor and advising Zest on 1800 795 695 or via email support@revestiveathome.com.au
• You understand that Takeda (the pharmaceutical company) provides this service to you and reserves the right to discontinue this service at any given time. In this case, Zest will inform you about this decision and discuss further details and options with you
• You understand that your personal information will be collected, stored, used and disclosed in accordance with Australian Privacy legislation and Takeda’s Privacy Notice. This information will only be shared with relevant parties providing this service in accordance with consent granted for data processing

Patient or parent/guardian consent to Terms and Conditions

By signing this form, you confirm that:

• You consent to participate in REVESTIVE atHOME and agree to the Terms and Conditions above
• I consent to the patient’s enrolment in REVESTIVE atHOME on the Terms and Conditions above

Terms and conditions

• The REVESTIVE Familiarisation Program has been explained to you by a representative of Shire
• You have received, read and are familiar with the REVESTIVE Product Information

• You may only enrol patients into the REVESTIVE Familiarisation Program who meet the eligibility criteria and are not contraindicated

  • Eligibility criteria

    REVESTIVE is indicated for the treatment of adult patients with Short Bowel Syndrome who are dependent on parenteral support. Patients should be stable at least to 4 weeks on their parenteral support regimen before initiating therapy¹

    Eligible patients must:

    • have Short Bowel Syndrome-Intestinal Failure (SBS-IF) following major surgery and have undergone a period of intestinal rehabilitation
    • have chronic Type III intestinal failure
    • be dependent on parenteral support (PS) for at least 12 months and receiving PS on at least 3 days per week
    • be under the supervision and direction of a medical specialist with experience in the management of SBS.

    REVESTIVE is contraindicated in patients who:¹

    • have an active gastrointestinal malignancy (gastrointestinal tract, hepatobiliary, pancreatic)
    • have a history of malignancies in the gastrointestinal tract including the hepatobiliary system within the last 5 years
    • are hypersensitive to the active ingredient (teduglutide) or to any of the excipients.

    Please refer to the REVESTIVE Product Information before prescribing.

• You agree to explain to your patients the risks and benefits of using REVESTIVE
• You agree to obtain informed consent from your patients to participate in the REVESTIVE Familiarisation Program
• A maximum of 14 eligible patients can be enrolled across the selected Intestinal Failure (IF) clinics across Australia who are being offered the opportunity to participate in the REVESTIVE Familiarisation Program. Each registered IF clinic will be guaranteed one patient enrolment place in the REVESTIVE Familiarisation Program and may enrol up to another two patients depending on the remaining slots available (determined by a first-come-first-served basis)
• The enrolment period for patients into the REVESTIVE Familiarisation Program may not exceed six months from the commencement of the Program, unless Shire extends the enrolment period
• Patients who are enrolled in the REVESTIVE Familiarisation Program will be provided with REVESTIVE at no charge until Pharmaceutical Benefits Scheme (PBS) reimbursement commences or when Shire decides to end the Program
• Medication charges (dispensing fees) may be charged by pharmacies and this will not be covered through the Program. Patients will only be able to transition to PBS-reimbursed REVESTIVE if they meet the PBS eligibility criteria
• During the Familiarisation Program, REVESTIVE will be continually supplied to enrolled patients for as long as it is determined by you that the patient is receiving a clinical benefit from their treatment. The REVESTIVE Familiarisation Program will continue until the start of PBS listing or until Shire no longer supplies REVESTIVE in Australia
• REVESTIVE prescriptions written as part of the Program may be dispensed by a hospital or retail pharmacy based on your hospital’s regulations and patient’s preference
• You understand that information relating to an adverse event with REVESTIVE that is identified during the Familiarisation Program will be forwarded to the drug safety department of Shire and to health authorities. You also consent for Shire or an authorised third party to contact you for further details regarding the adverse event, if required
• You agree to notify ZEST Healthcare Communications immediately and return a Patient discontinuation form (by email to support@revestiveathome.com.au, fax to 1800 807 961 or online at www.revestiveathome.com.au) if any of your patients discontinue treatment or require a break from treatment
• You understand that if your patient discontinues or requires a break from the REVESTIVE Familiarisation Program, you may be able to enrol another patient in the Program during the patient enrolment period or recommence the discontinued patient (using the Patient continuation form)
• You are under no obligation to prescribe or recommend REVESTIVE at any time, and you will not receive any payment or reward for your participation in the REVESTIVE Familiarisation Program
• Any current restrictions or conditions imposed by the Australian Health Practitioner Regulation Agency (AHPRA) on your practising certificate have been disclosed to Shire. Once enrolled in the REVESTIVE Familiarisation Program, you will inform Shire within 14 days of being notified by AHPRA if you become subject to any conditions or restrictions on your practising certificate. To your knowledge, you are not subject to any professional disciplinary enquiries or patient complaints

Eligibility criteria

REVESTIVE is indicated for the treatment of adult patients with Short Bowel Syndrome who are dependent on parenteral support. Patients should be stable at least to 4 weeks on their parenteral support regimen before initiating therapy¹

Eligible patients must:

• have Short Bowel Syndrome-Intestinal Failure (SBS-IF) following major surgery and have undergone a period of intestinal rehabilitation
• have chronic Type III intestinal failure
• be dependent on parenteral support (PS) for at least 12 months and receiving PS on at least 3 days per week
• be under the supervision and direction of a medical specialist with experience in the management of SBS.

REVESTIVE is contraindicated in patients who:¹

• have an active gastrointestinal malignancy (gastrointestinal tract, hepatobiliary, pancreatic)
• have a history of malignancies in the gastrointestinal tract including the hepatobiliary system within the last 5 years
• are hypersensitive to the active ingredient (teduglutide) or to any of the excipients.

Please refer to the REVESTIVE Product Information before prescribing.

Last updated in March 2023

Your privacy and the protection of your personal data is important to us. This Privacy Notice explains the type of personal data we may collect from you and how we use it.

This website is provided to you by Zest.

This website provides information and/or services intended only for healthcare professionals and patients who have been prescribed REVESTIVE^® (teduglutide) and wish to or have been enrolled in REVESTIVE atHOME^®.

Where you use any service provided on this website, we collect and process personal data that you provide to us to respond to and/or fulfil your requests, or perform our obligations to you. We may also use personal data as may be needed to comply with our legal obligations. Where you provide personal data of others to us, you undertake to ensure that such others have been informed of your disclosure to us, and that their personal data may be processed by us in accordance with this Privacy Notice. We may not be able to provide you responses or services requested if relevant personal data is not collected.

When you visit this website and/or access any content provided on it, we may also automatically collect technical information such as your internet protocol (IP) address, information on how you use this website, and your device.

The personal data collected may be shared with service providers and business partners around the world with whom we collaborate to fulfil the above purposes.

This may include disclosing your personal information to the following types of third parties:

• our related companies;
• health service providers or treating health professionals (such as your doctor, pharmacist or hospital), in connection with providing health-related goods or services to you;
• our contractors and other third parties that provide goods and services to us;
• manufacturers or suppliers of pharmaceutical products;
• in an emergency, to medical and health service providers;
• otherwise as permitted or required by law.

The sharing of personal data may involve transfers to other countries. The data protection and privacy laws in such countries may provide a different level of protection. We will put in place appropriate safeguards to protect personal data in connection with such transfers.

We keep personal data for the period necessary in relation to the above purposes. We may also keep personal data for a reasonable period following the fulfilment of our services to you, termination of your relationship with us, or the discontinuation of your use of our application, unless a longer retention period is required or permitted by law.

Our processing of personal data as described above may be for our legitimate interests in managing our products, services, and business; to respond to your requests or queries or fulfil our contractual obligations towards you; to comply with our legal obligations; or based on your consent.

You may have the right to request access to, rectification, erasure, and/or a transfer of your personal data, or object to or request restriction of its processing. Where our use of your personal data is based on your consent, you may also have the right to withdraw your consent at any time. To exercise any right available to you, please contact:

• The Zest Privacy Officer via email at privacy@symbion.com.au
• The ASCOTT Privacy Officer via privacyofficer@iqvia.com

If you have a complaint about the processing of your personal data, you may also contact the data protection supervisory authority of the territory you are based in.
For more detailed information on how Zest uses, stores and discloses personal data, please refer to Zest’s Privacy Policy at www.zest.com.au/privacy-policy.

Welcome to the Takeda Healthcare Professional website for www.revestiveathome.com.au (the “Website”). The information provided on this Website is about Takeda and its patient support programs. It is for program administration, general information and education purposes only. Please read and review these Terms of Use carefully before accessing and using this Website.

All information presented on this Website is solely intended for healthcare professionals, like yourself, in relation to the REVESTIVE^® atHOME^® program.

This Website may also contain general information relating to Takeda product(s), various medical conditions and their treatment. Such information is for educational and informational purposes only and it is not intended as a substitute for informed medical advice or recommendations from healthcare professionals. It should not be relied on as a basis for making any decision or taking any actions.

1. Use of Takeda Website

Your access to, and use of, this Website is governed by the following terms and conditions and all applicable laws. By using any of the contents of this Website, including but not limited to, all text and images, graphics, logos, icons, and video clips (the “Contents”) you hereby acknowledge that you have read, understood and agreed, without limitation or qualification, to these Terms of Use and acknowledge that any other agreements between you and Takeda Pharmaceuticals Australia Pty Ltd having its offices at Grosvenor Place, Level 39, 225 George Street, Sydney NSW 2000 Australia (“Takeda”) are superseded with respect to this subject matter.

This Website may contain specific information relating to various Takeda medicines including, but not limited to, prescription only medicines. Please note that approved prescribing information must guide the appropriate use of all medicines, and before prescribing any medicine, Healthcare Professionals should consult the approved prescribing information for that medicine in their country.

This Website may contain information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths and subject to different regulatory requirements depending on the country of use. Many of the products listed are available only by prescription through Healthcare professionals.

All information and references relating to handling, storage or use of products, to be implied from the relevant resource, are based on Takeda's knowledge at the time such information is provided.

The information provided on this Website does not constitute an offer of, or solicitation for, the purchase, disposal of, trading, or any transaction in any Takeda securities, its affiliates and/or partners’ securities. Investors must not rely on this information for investment decisions.

2. Use of Contents and Intellectual Property Rights

The entire Contents of this Website are subject to the relevant trademark and copyright protection. The trademarks, logos and service marks (collectively, the "Trademarks") used or mentioned on this site are registered and unregistered trademarks of Takeda, one of its affiliates and/or partners and are protected by applicable law. You may download, display or print information from this Website solely for non-commercial personal use or for use in non-commercial education and scientific work. No modification for further reproduction of the content is permitted and all copyright and other proprietary notices contained herein shall be retained in all copies. The content may otherwise not be copied or used in any way without the prior written consent of Takeda or except as provided in these Terms of Use. This Website and all of its Contents are owned by Takeda, its affiliates and/or partners. All rights reserved.

Other than the limited right to use the Website and all of its Contents in accordance with these Terms of Use, no license to, or right in, the Website and/or the Contents or any trademarks, patents, designs, trade secrets, technologies, products, process and other proprietary rights of Takeda, its affiliates and/or partners is granted to or conferred upon you.

3. Information “as is”

Takeda will use reasonable efforts to include accurate and up-to-date information on this Website but, to the extent permitted by applicable law, makes no warranties or representations of any kind as to its accuracy, currency or completeness.

To the extent permitted by applicable law, Takeda disclaims all warranties, expressed or implied, including warranties of acceptable quality or fitness for a particular purpose. Furthermore, Takeda neither warrants nor represents that your use of any of the Contents on this Website will not infringe rights of third parties, not owned by Takeda or any of its affiliates. You agree that access to and use of this Website and the Contents thereof is at your own risk.

4. Disclaimed liability

To the maximum extent permitted by law, neither Takeda nor any party involved in creating, producing or delivering this Website shall be liable for any damages or injury including, without limitation, direct, indirect, incidental, consequential, punitive, and special or other damages, lost opportunities, lost profit or any loss or damages of any kind arising out of access to, use of, or inability to use, this Website, or any errors or omissions in the Contents thereof. This limitation includes damages to, or any viruses that may affect, your computer equipment, and this limitation applies to the fullest extent permitted by applicable law.

Nothing in these Terms of Use excludes, restricts or modifies any right, remedy, guarantee, warranty or other term or condition implied or imposed by the Australian Consumer Law which cannot be lawfully excluded or limited. The limitations outlined above, and anywhere else in those document, will not operate to the extent they are inconsistent with those statutory guarantees.

Takeda’s liability for breach of any warranty or statutory guarantee implied into these Terms of Use by statute which cannot be excluded is limited (where permitted by applicable law) to the supply of that part of the Website again or, at Takeda’s option, the payment of the costs of having an equivalent service supplied again.

5. Data Privacy

Your personal data may be processed when you visit or use this website. Please refer to REVESTIVE atHOME Website Privacy Notice for information on how your personal data may be processed when you visit or use this website, and your rights in respect of the same.

6. Links to other internet sites

This Website may contain links or references to other internet sites maintained by third parties over which Takeda has no control. Such links are provided merely as a convenience. Similarly, this Website may be accessed from third party links over which Takeda has no control. Your use of such third-party internet sites is subject to the terms of use and privacy policies of those websites, and your access to and use of those sites is at your own risk.

Accordingly, Takeda makes no warranties or representations of any kind as to the truthfulness, accuracy, currency, completeness of any information contained, or compliance with, applicable law in such third-party internet sites and assumes no liability for any damages or injuries of any kind arising from such content or information. Inclusion of any third-party links does not imply any endorsement or recommendation by Takeda.

7. Use of Questions and Comments

Except for transmissions covered by our Privacy Notice or made by Healthcare Professionals pursuant to the applicable laws, regulations and codes, communications which you forward to this Website or otherwise transmit to Takeda on or through this Website shall be deemed non-confidential and non-proprietary and Takeda shall not be required to respond. Subject to the applicable laws, Takeda and its affiliates reserve the right to use such communications of a non-confidential nature for any purpose and to reproduce, publish and disclose this information to third parties without limitation or compensation.

8. Applicable law and place of jurisdiction

For any breaches of the terms and conditions in the Terms of Use, Takeda reserves the right to take corrective action including, but not limited to, suspending or terminating access to the Website (such as if you knowingly transmit any virus to this Website, or impersonate any person when using or accessing the Website) and removing any information, data and content communicated to this Website, at any moment and without notice.

These Terms of Use, the Contents of this Website and your use of it shall be governed by and construed in accordance with substantive laws of New South Wales, Australia. Any conflict arising out of, or in relation hereto, if not solved amicably, shall be settled by courts of competent jurisdiction in New South Wales.

In case any part of these Terms of Use is held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired.

9. Uploading content

If some features of the Website allow you to upload content to the Website, you must not upload or otherwise transmit or distribute material which breaches any law, which infringes any third-party rights, which is defamatory, discriminatory, obscene, offensive, misleading, deceptive, inflammatory or which is threatening, abusive or invasive of another person’s privacy. You warrant that you are the owner or authorised user of the materials you upload.

You must ensure that all information provided by you and uploaded to the Website is and remains accurate and complete.

You must not transmit to or via the Website any virus or other information or otherwise use the Website in a way which tampers with, hinders the operation of, or makes unauthorised modifications to the Website, or inhibits any other user from using the Website.

10. Update of the Terms of Use and other policies provided on this Takeda Website

Takeda reserves the right to update, alter or delete material from the Website at any time, and Takeda may, at any time, revise these Terms of Use and/or any other policies set forth in this Website by updating this posting. By using the Website, including accessing the Website, you accept all of its Terms of Use and should, therefore, periodically visit this page to review the then current Terms of Use and policies.

The copyright and ownership of this Website reside with:

TAKEDA PHARMACEUTICALS AUSTRALIA PTY LTD
Suite 3901, Level 39,
Grosvenor Place,
225 George Street, Sydney,
New South Wales 2000, Australia